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Summary The clinical use of all-trans-retinoic acid (ATRA) in the treatment of cancer is significantly hampered by the prompt emergence of
resistance, believed to be caused by increased ATRA catabolism. Inhibitors of ATRA catabolism may therefore prove valuable for cancer
therapy. Liarozole-fumarate is an anti-tumour drug that inhibits the cytochrome P450-dependent catabolism of ATRA. ATRA, but also its
naturally occurring catabolites, 4-oxo-ATRA and 5,6-epoxy-ATRA, as well as its stereoisomers, 9-cis-RA and 13-cis-RA, show significant
antiproliferative activity in MCF-7 human breast cancer cells. To further elucidate its mechanism of action, we investigated whether liarozole-
fumarate was able to enhance the antiproliferative activity of ATRA catabolites and isomers. Liarozole-fumarate alone up to a concentration
of 10-6 M had no effect on MCF-7 cell proliferation. However, in combination with ATRA or the ATRA catabolites, liarozole-fumarate (106 M)
significantly enhanced their antiproliferative activity. On the contrary, liarozole-fumarate (10-6 M) was not able to potentiate the antiproliferative
activity of the ATRA stereoisomers, most probably because of the absence of cytochrome P450-dependent catabolism. Together, these
findings show that liarozole-fumarate acts as a versatile inhibitor of retinoid catabolism in that it not only blocks the breakdown of ATRA, but
also inhibits the catabolic pathway of 4-oxo-ATRA and 5,6-epoxy-ATRA, thereby enhancing theirantiproliferative activity.
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The therapeutic potential of all-trans-retinoic acid (ATRA) in
cancer is obvious from a vast number of publications (for review
see Hong and Itri, 1994; Moon et al, 1994). However, a major
drawback to the clinical application of ATRA is the prompt emer-
gence of resistance, most probably because of the induction of
oxidative catabolism through cytochrome P450-dependent
enzymes (Muindi et al, 1992; Smith et al, 1992; Warrell et al,
1993; Warrell, 1993; Kizaki et al, 1996).
Liarozole-fumarate, an imidazole-containing anti-tumour drug,
was recently identified as an inhibitor of cytochrome P450-depen-
dentretinoic acid(RA) catabolism (VanWauwe etal, 1990; Wouters
et al, 1992; Van Wauwe et al, 1994; Krekels et al, 1996). In vivo,
liarozole-fumarate showed retinoid-mimetic effects (Van Wauwe et
al, 1991; Mahler et al, 1993; Smets et al, 1995). In animals, the
drug reduced the growth ofboth androgen-dependent and androgen-
independent Dunning R3327 rat prostate adenocarcinoma cells
(Van Ginckel et al, 1990; Steams et al, 1993; Smets etal, 1995), and
of androgen-independent PC-3ML-B2 human prostate carcinoma
xenografts (Dijkman et al, 1994). In the Dunning AT-6sq, an
androgen-independent rat prostate carcinoma, liarozole-fumarate
reduced tumour weight, and concomitantly increased ATRA levels
both in plasma and in tumours, resulting in a shift oftheir differenti-
ation status (Smets et al, 1995). In patients, the drug is currently
being tested in phase Ill clinical trials for the treatment ofrelapsed
prostate cancer (Mahler et al, 1993; Wouters, 1994).
Received21 July 1997
Accepted 6 October 1997
Correspondence to: Van heusden, Janssen Research Foundation,
Department of Oncology, Turnhoutseweg 30, B-2340 Beerse, Belgium.
In vitro, liarozole-fumarate has no intrinsic retinoid-like activity,
but enhances the beneficial effects of ATRA, most probably by
inhibiting catabolism. The drug has been shown to potentiate the
antiproliferative activity of ATRA in MCF-7 human breast cancer
cells (Wouters et al, 1992; Van heusden et al, 1996) and to enhance
the differentiation-inducing capacity of ATRA in F9 mouse terato-
carcinoma cells (De Coster et al, 1992) and MCF-7 cells (Van
heusden etal, 1996). The cancerchemopreventive activity ofATRA
and [B-carotene was potentiated in 10T1/2 mouse embryonal fibrob-
lasts (Acevedo and Bertram, 1995) and retinoid-induced apoptosis
was enhanced in DU145 human prostate cancercells (Hall, 1996).
ATRA is well known to inhibit proliferation and to induce
differentiation of malignant cells (Lotan, 1980). ATRA is rapidly
metabolized in a catabolic pathway that includes the 4-hydroxyla-
tion of the f-ionone ring to yield 4-hydroxy-ATRA (Frolik et al,
1979, Roberts et al, 1980). This step is catalysed by a cytochrome
P450-dependent ATRA 4-hydroxylase (Roberts et al, 1980; White
et al, 1996). 4-Hydroxy-ATRA is then converted to more polar
metabolites via 4-oxo-ATRA (Roberts et al, 1980), involving at
least one, presently unknown, cytochrome P450-dependent
enzyme (Roberts et al, 1980; Van Wauwe et al, 1994). Other cata-
bolic pathways of ATRA have been described including epoxida-
tion to yield 5,6-epoxy-ATRA (McCormick et al, 1978; Barua et
al, 1991). Also, ATRA can isomerize in cell culture to 9-cis-RA
and 13-cis-RA, an obviously non-enzymatic process (Urbach and
Rando, 1994). ATRA and its naturally occurring catabolites and
isomers possess significant antiproliferative activity in MCF-7
cells (Van heusden et al, 1998). To further explore its mechanism
of action, we studied whether liarozole-fumarate was able to
enhance the antiproliferative activity of these naturally occurring
ATRA catabolites and isomers.
12291230 J Van heusden etal
MATERIALS AND METHODS
Drugs and chemicals
The fumarate salt of liarozole, {±-5-[(3-chlorophenyl)(1H-imida-
zole-1-yl)methyl]-lH-benzimidazole (E)-2-butenedioate (2:3)}
(R085246), was synthesized at the Janssen Research Foundation
(Beerse, Belgium). ATRA was obtained from Serva (Heidelberg,
Germany) and 13-cis-RA was purchased from Eastman Kodak
(Rochester, NY, USA). 9-cis-RA, 4-oxo-ATRA and 5,6-epoxy-
ATRA were generous gifts from Dr M Klaus (Hoffmann-La-
Roche, Basle, Switzerland). Stock solutions of liarozole-fumarate
(10 mm) and retinoids (4 mM) were prepared in ethanol and appro-
priately diluted in culture medium. The final ethanol concentration
did not exceed 0.5% (v/v). The retinoid stock solutions were
checked for purity using high-performance liquid chromatography
(HPLC) analysis. Experimental studies with retinoids were always
performed in a dark room with yellow illumination.
Preparation of dextran-coated charcoal (DCC)-treated
fetal bovine serum (FBS)
DCC-treated FBS was prepared as described by Horwitz and
McGuire (1978). Briefly, FBS (Life Technologies, Paisley, UK)
was heat-inactivated by a 30 min incubation at 56°C. Activated
charcoal [0.25% (w/v); Sigma Chemical, St Louis, MO, USA] was
coated overnight at 4°C with dextran [0.025% (w/v); Pharmacia,
Uppsala, Sweden] in 0.01 M Tris-HCl (pH 8.0). Then, 100 ml of
this suspension was pelleted by centrifugation and 50 ml of heat-
inactivated FBS was incubated for 45 min at 450C with the
resulting DCC pellet. This procedure was repeated and finally the
activated charcoal was removed from the FBS by centrifugation.
DCC-treated FBS was sterilized by passage through a 0.22 jim
Millipore filter (low protein binding) and stored at-20°C until use.
The efficiency ofthis procedure was assessed by the addition of a
trace amount of [6, 7 - 3H(N)]oestradiol (DuPont NEN, Boston,
MA, USA), [11, 12 - 3H(N)]retinol (DuPont NEN) and [11, 12 -
3H(N)]ATRA (DuPont NEN). The DCC-treatment efficiently
removed oestradiol and ATRA, and retinol to a lesser extent (Van
heusden et al, 1998).
Cell culture
Stock cultures ofMCF-7 human breast cancercells, purchased from
the American Type Culture Collection (Rockville, MD, USA), were
cultured in Dulbecco's modified Eagle medium (DMEM) with4.5 g
1-1 glucose supplemented with 10% (v/v) FBS, 2 mM L-glutamine,
1 mm sodium pyruvate and 50 jig ml-' gentamicin (all reagents from
Life Technologies). The MCF-7 subclone used in this study has
been characterized previously (Van heusden et al, 1996). Cells were
grown in a humidified incubator (5% carbon dioxide, 95% air) at
37°C and were Mycoplasma free as tested by the Mycoplasma TC
kit (Gen-Probe Incorporated, CA, USA).
For the proliferation studies, MCF-7 cells were cultured for
6 days in phenol red-free DMEM containing 5% (v/v) DCC-
treated FBS, 4.5 g 1-1 glucose, 2 mM L-glutamine, 1 mm sodium
pyruvate, 50 jg ml-'gentamicin, 30 nm sodium selenite and 10 jg
ml-' transferrin (all reagents from Life Technologies). Cells were
seeded onto Chamber Slides (Nunc, Naperville, IL, USA) at a
concentration of 15 000 cells per chamber. Chamber Slides had
been coated with 50 jg ml-' poly-L-lysine one day before use.
Cells were allowed to attach for 24 h, and thereafter the medium
was supplemented with growth factors, i.e. 10 ,ug ml-' final
concentration insulin (Life Technologies) and 5 ng ml final
concentration basic fibroblast growth factor (Life Technologies),
retinoids (concentration ranging from 10-"1 M to 106 M) and liaro-
zole-fumarate (concentration ranging from 10-7 M to 10-5 M). Cells
were grown under these conditions for 7 days with medium
changes 3 and 6 days after seeding.
Bromodeoxyuridine (BrdU) detection
Cell proliferation was measured using BrdU incorporation, which
is considered an accurate method because it is a direct assay of
DNA synthesis (Dolbeare, 1995). After 7 days of culture with
retinoids as described above, MCF-7 cells were labelled with
100gM BrdU for 2.5 h and fixed. Incorporated BrdU was visual-
ized by immunofluorescence staining using the tyramide signal
amplification (TSA)-direct kit (Green) (DuPont NEN Life Science
Products, Boston, MA, USA) as described in detail previously
(Van heusden et al, 1997).
The BrdU labelling index was defined as the proportion of
BrdU-positive cells, representing cells in S-phase, and was esti-
mated by counting cells under a fluorescence microscope
(Axiophot, Zeiss, Germany) with a dual filter set for simultaneous
visualization of fluorescein and propidium iodide signals. About
800 cells were counted twice for each test compound per experi-
ment. Average results are presented as means ± s.d. ofthree to five
experiments.
Microcolumn assay for ATRA catabolism
ATRA catabolism was quantitatively determined using the micro-
column assay as described previously (Krekels et al, 1997).
Briefly, cells cultured in medium containing 5% DCC-treated
FBS, were pretreated for 24 h with I06 M ATRA to induce the
ATRA catabolic pathway (Wouters et al, 1992; Krekels et al,
1997). Cells were then washed with culture medium, harvested
andresuspended at4 x 106 cells ml-'. This cell suspension (450 il)
was incubated for 90 min in the presence of 10-7 M [11, 12 -
3H(N)]ATRA or 10-7 M [3H]9- cis-RA (Amersham Life Science,
Buckinghamshire, UK), and thereafter 2 ml of 100% acetonitrile
was added. After centrifugation for 10 min at 780 G, the resulting
deproteinized supernatant was acidified with 2.5 ml of 40 mm
acetic acid and applied to a 3 ml of C18 Bond Elut ??RC column
(Varian, Harbor City, CA, USA; pretreated with 4 ml of distilled
water) under a vacuum of 127 mmHg using VAC ELUT SPS-24
andtheeffluent was collected. Thecolumn was eluted with 1 ml of
40% acetonitrile and the effluent was collected in the same vial.
The collected effluent, containing the polar metabolites, was
counted for radioactivity in a Packard Tri-carb 4530 liquid scintil-
lation analyser. Optiphase 'Hi Safe II' (Wallac, Milton Keynes,
UK) was used as a scintillator.
HPLC analysis
The MCF-7 cell suspension was prepared as described above and
450 ,ul was incubated with 10-7 M [11, 12 -3H(N)]ATRA or 10-7M
[3H]9-cis-RA for 4 h. After centrifugation for 10 min at 780g, the
supernatant was analysed for the presence of ATRA metabolites
and isomers.
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Analysis ofATRA metabolites
Reverse-phase HPLC analysis was carried out on a Varian HPLC
system consisting of a HPLC pump 9010, an autosampler 9095
and a diode array detector (Polyview, 9065). The Star4.0 data soft-
ware (Varian) was used to analyse the chromatograms.
Radioactivity in the eluate was monitored on-line by p-counting
(Packard Radiomatic radioactivity monitor) using Ultima-flo M
(Packard, Meriden, CT, USA) as the scintillation solvent. The
samples (150 p1) were analysed on a Zorbax 5C8 column (4.6 mm
i.d. x 250 mm, 5 gm; Chrompack). The mobile phase was
methanol-2% acetic acid-acetonitrile (1.5:93:5.5) containing
40 mM ammonium acetate (solvent A). Solvent B consisted of
methanol-2% acetic acid-acetonitrile (15:30:55) containing
40 mm ammonium acetate and solvent C was 100% methanol. A
linear gradient at a flow rate of 1 ml min-m was performed in
25 min from 24% A-76% B to 15% A-85% B. The solvent was
then changed to 50% B - 50% C in 15 min. To elute unchanged
ATRA the solvent was then changed to 100% C after 40 min.
Analysis ofATRA isomers
For the separation ofthe isomers ofATRA the same HPLC equip-
ment was used. Samples (150gl) were analysed on a Novapak
column (3.9 mm i.d. x 300 mm). Solvent D was methanol-2%
acetic acid-acetonitrile (15:30:55) containing 40 mM ammonium
acetate. Solvent E consisted of methanol-2% acetic acid-acetoni-
trile (20:20:60) containing 40 mm ammonium acetate and solvent
F was 100% methanol. The mobile phase was 50% D - 50% E for
30 min at a flow rate of 1 ml min-'. Then a linear gradient was
performed to 100% F.
Statistical analysis
Data were analysed using the two-tailed Mann-Whitney U-test
using the Stat View II software (Abacus Concepts, Berkeley,
CA, USA). Significance was defined at the level of *P < .01 and
**P < .001.
RESULTS
Liarozole-fumarate potentiates the antiproliferative
activity of ATRA and its catabolites, but not of its
stereoisomers
MCF-7 cells were cultured in steroid- and retinoid-free medium
supplemented with growth factors. Under these culture conditions,
MCF-7 cells showed a BrdU labelling index of25.2± 1.4% (n = 5).
Liarozole-fumarate alone had no effect on MCF-7 cell proliferation
up to a concentration of 106 M (Figure IA). At 10-5 M, liarozole-
fumarate decreased theBrdU labelling index to 21.5 ± 2.8% (n =4).
In all following experiments liarozole-fumarate was therefore used
at a concentration of I0- M.
Liarozole-fumarate (10-6 M) significantly enhanced the antipro-
liferative activity of ATRA (Figure IB) and its naturally occurring
catabolites 4-oxo-ATRA (Figure IC) and 5,6-epoxy-ATRA (Figure
ID) as reflected by a further decrease in the BrdU labelling index.
This potentiation was more pronounced at lower retinoid concen-
trations. Note that liarozole-fumarate was not able to enhance the
antiproliferative activity atretinoid concentrations of 10 6M (Figure
B -D). In the case of5,6-epoxy-ATRA, liarozole-fumarate was not
able to enhance the antiproliferative activity at concentrations of
10-7 M and 10- M (Figure 1 D). Liarozole-fumarate (106 M) did not
enhance the antiproliferative activity ofthe stereoisomers 9-cis-RA
(Figure lE) and 13-cis-RA (Figure IF).
5,6-Epoxy-ATRA competes with ATRA for ATRA
catabolism
MCF-7 cells, cultured in medium containing 5% DCC-treated
FBS, were pretreated for 24 h with 106 M ATRA to induce ATRA
catabolism (Wouters etal, 1992; Krekels et al, 1997). ATRA catab-
olism was measured using 10-7 M [3H]ATRA as substrate. As
shown in Figure 2, non-radioactive ATRA competed with
[3H]ATRA with an IC50 value of 129 ± 40 nM (n = 5). 5,6-Epoxy-
ATRA was a better competitor than ATRA and decreased the
amount ofpolar [3H]ATRA metabolites with an IC50 value of50±
28 nM(n = 5).
Liarozole-fumarate inhibits the catabolism of ATRA
Liarozole-fumarate concentration dependently increased the level
of unmetabolized [3H]ATRA and concomitantly inhibited the
formation ofpolar [3H]ATRA metabolities (Figure 3, Table 1). The
unidentified apolar peak was concentration dependently increased
by liarozole-fumarate. The isomerization process ofATRA to 9-cis-
RA and 13-cis-RA was notaffectedby liarozole-fumarate (Table 1).
A peak co-eluting with 4-oxo-ATRA was formed to only a limited
extent (data not shown). No peak co-eluting with authentic 5,6-
epoxy-ATRA could be detected with or without treatment with
liarozole-fumarate at concentrations from 106 M to l0-5 M.
9-cis-RA is not metabolized in MCF-7 cells
[3H]9-cis-RA was not converted to polar metabolites in MCF-7
cells as measured by HPLC analysis. Similarresults were obtained
by the microcolumn assay (data not shown). The metabolism of
13-cis-RA, 4-oxo-ATRA and 5,6-epoxy-ATRA could not be
studied because these retinoids are not available as tritiated
compounds and unlabelled retinoids could not be used for these
purposes (data not shown; Gubler and Sherman, 1990).
DISCUSSION
The present study further elucidates the mechanism of action of
liarozole-fumarate by showing its enhancing effect on the antipro-
liferative activity of naturally occurring ATRA catabolites. These
effects could only beproperly studied in a steroid- andretinoid-free
culture medium supplemented with growth factors. We have previ-
ously demonstrated that not only ATRA itself, but also its naturally
occurring catabolites, 4-oxo-ATRA and 5,6-epoxy-ATRA, as well
as its stereoisomers, 9-cis-RA and 13-cis-RA, significantly inhibit
the proliferation ofMCF-7 human breast cancercells (Van heusden
et al, 1998). Liarozole-fumarate, at a concentration of 106 M,
enhanced the antiproliferative activity ofATRA and its catabolites,
but not that of the stereoisomers of ATRA. As such liarozole-
fumarate acts as a versatile inhibitor of the cytochrome P450-
dependent ATRA catabolic pathway (Figure 4).
Liarozole-fumarate (I06 M) significantly enhanced the antipro-
liferative activity ofATRA in MCF-7 cells. This potentiating effect
was more than 100-fold at low retinoid concentrations (10-10 M to
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Figure 1 Concentration response curves showing the effect of liarozole-fumarate alone (A) or in combination with ATRA (B), 4-oxo-ATRA (C), 5,6-epoxy-
ATRA (D), 9-cis-RA (E) and 13-cis-RA (F) in MCF-7 cells. Cells were cultured for 7 days in the presence of test compounds. Cell proliferation was measured by
BrdU incorporation, as described in Materials and methods. Results are presented as means ± s.d. of three (B, E, F), four (A) or five (C, D) experiments. *P <
.01 and **P < .001 vs control cells (Mann-Whitney U-test). #P < .05 and "P < .01 vs retinoid-treated cells (Mann-Whitney U-test). (A) 0, Liarozole-fumarate. (B)
0, ATRA; V, ATRA + 1 gM liarozole-fumarate. (C) 0, 4-oxo-ATRA; V, 4-oxo-ATRA + 1 gM liarozole-fumarate. (D) 0, 5,6-epoxy-ATRA; V, 5,6-epoxy-ATRA + 1
1M liarozole-fumarate. (E) 0, 9-cis-RA; V, 9-cis-RA + 1 gM liarozole-fumarate. (F) 0, 13-cis-RA; V, 13-cis-RA + 1 gM liarozole-fumarate
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Figure 2 Competition between radioactive [3H]ATRA and non-radioactive
ATRA (IC50 = 129 + 40 nM) and 5,6-epoxy-ATRA (IC50 = 50 + 28 nM). MCF-7
cells were preincubated for 24 h with 10-6 M ATRA to induce ATRA
catabolism. Concentration response curves for ATRA catabolism were
determined using 1Q-7 M [3H]ATRA as substrate. Results are presented as
means ± s.d. offive experiments. *P< .01 vs control. #P< .05 vs ATRA
treatment (Mann-Whitney lUtest), 0, ATRA; 0, 5,6-epoxy-ATRA
10-9 M) in contrasttothetenfoldenhancement, aspreviously demon-
strated under growth conditions with culture medium containing
untreated FBS (Wouters et al, 1992; Van heusden et al, 1996). The
effect of liarozole-fumarate on ATRA metabolism was analysed
using HPLC. Only the supematant was studied. We havepreviously
shown that in thecell extract the same overall metaboliteprofile can
be found (Wouters et al, 1992). Liarozole-fumarate increased the
level ofRA and concomitantly inhibitedtheformation ofmorepolar
metabolites in a concentration-dependent manner. Together, these
findings suggest that liarozole-fumarate enhances the antiprolifera-
tiveactivity ofATRAbyinhibitingitscatabolism, in agreement with
ourprevious findings (Wouters et al, 1992).
Liarozole-fumarate (106 M) enhanced the antiproliferative
activity of the naturally occurring catabolite 4-oxo-ATRA,
confirming that its catabolism is inhibited by liarozole-fumarate.
Indeed, Van Wauwe et al (1994) have shown that liarozole-
fumarate inhibited the formation ofmorepolarmetabolites from4-
oxo-ATRA in hamster liver microsomes. In addition,
liarozole-fumarate enhanced the plasma half-life of 4-oxo-ATRA
in rats (Van Wauwe et al, 1994). Taken together, these findings
suggest that catabolism of 4-oxo-ATRA involves at least one
cytochrome P450-dependent enzyme (Roberts et al, 1980; Van
Wauwe et al, 1994) that is inhibited by liarozole-fumarate.
The antiproliferative activity of low concentrations of 5,6-
epoxy-ATRA was also potentiated by liarozole-fumarate (106 M).
One possible explanation for this synergism is that liarozole-
fumarate inhibits the cytochrome P450-dependent catabolism of
5,6-epoxy-ATRA. Although such enzyme(s) are unknown, it is not
unlikely that 5,6-epoxy-ATRA is metabolized by the same
enzyme(s) as ATRA as 5,6-epoxy-ATRA was a better competitor
than ATRA itself in our assay for measuring ATRA catabolism.
Although liarozole-fumarate was present at a tenfold higher
concentration, i.e. 10-6 M, the drug was not able to enhance the
antiproliferative activity of 5,6-epoxy-ATRA when tested at a
concentration of I0-7 M. These data support the hypothesis that
both liarozole-fumarate and 5,6-epoxy-ATRA compete for the
same enzyme(s) and that the higher affinity of 5,6-epoxy-ATRA
for these enzyme(s) does not allow enhancement.
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Figure 3 Chromatograms illustrating the metabolism of [3H]ATRA in the
absence (A) or presence of liarozole-fumarate at a concentration of 10-6 M
(B) or 10-5 M (C). Cells were incubated for 24 h with 10-6 M ATRA to induce
ATRA catabolism, washed twice and collected. Cells were then incubated for
4 h with 10-7 M [3H]ATRA and the supernatant was analysed using reverse
phase high-performance liquid chromatography (HPLC). I, very polar
metabolites; II, intermediate polar metabolites; III, apolar metabolite
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Table 1 Quantitative analysis of [3H]ATRA metabolism in MCF-7 cells
Radioactivity (%)
HPLC peaks Control + 10-6 M liarozole + 10-5 M liarozole
RA (% ATRA, 9-cis-RA 43 52 73
and 13-cis-RA) (78, 13, 10) (78,13,10) (82, 10, 9)
Metabolites
Very polar 36 28 10
Intermediately polar 15 12 5
Apolar 6 8 12
COOH
13-cis-retinoic acid
16 17 19 20
1 7 ii 1
2 6 COOH *-*10 sI8901134
34 18N
all-trans-retinoic acid
COOH
9-cis-retinoic acid
COOH
5,6-epoxy-all-trans-retinoic acid
More polar metabolites
COOH
OH
4-hydroxy-all-trans-retinoic acid
COOH
0
4-oxo-all-trans-retinoic acid
More polar metabolites
Inhibitions by liarozole-fumarate
Figure 4 Proposed mechanism of action of liarozole-fumarate. The drug acts as a versatile inhibitor at different steps of the ATRA catabolic pathway.
Liarozole-fumarate not only inhibits the catabolism of ATRA, but also of its catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA, thereby enhancing their
antiproliferative activity
The ability of ATRA to isomerize in cell culture has been
described before (Urbach and Rando, 1994). Liarozole-fumarate
(106 M) had no effect on isomerization ofATRA. The antiprolifer-
ative activity of9-cis-RA and 13-cis-RA could notbe enhanced by
liarozole-fumarate (10- M). In contrast, in vivo liarozole-fumarate
has been shown to enhance plasma levels of 9-cis-RA (Achkar et
al, 1994) and 13-cis-RA (Westarp et al, 1994). As RA catabolism
may be cell specifically regulated, the most likely explanation for
this discrepancy is the absence of cytochrome P450-dependent
enzymes that catabolize 9-cis-RA and 13-cis-RA in MCF-7 cells.
In favour of this hypothesis is our finding that 9-cis-RA was not
converted to polar metabolites in these cultures. Although, we
have previously shown that 9-cis-RA and 13-cis-RA can isomerize
to ATRA in MCF-7 cells (Krekels et al, 1997), the fact that their
antiproliferative activity was not potentiated by liarozole-
fumarate, indicates that their effect on MCF-7 cell proliferation
was not due to conversion to ATRA.
We have shown thatboth 9-cis-RA and 13-cis-RA compete with
ATRA in our assay for measuring ATRA catabolism in MCF-7
cells (Krekels et al, 1997). In this study, we show that liarozole-
fumarate was not able to enhance the antiproliferative activity of
these stereoisomers. Taken together, these findings suggest that
although both stereoisomers are able to bind to ATRA-catabo-
lizing enzyme(s), they are not used as substrates by these
enzyme(s) because then an enhancing effect by liarozole-fumarate
would be expected. These latter data are in agreement with the
observations ofDuell et al (1996) in mouse skin.
In conclusion, we can state that liarozole-fumarate is not only
able to inhibit the catabolism of ATRA but also that of 4-oxo-
ATRA and 5,6-epoxy-ATRA, thereby enhancing their antiprolifer-
ative activity. Liarozole-fumarate does not enhance the
antiproliferative activity ofthe stereoisomers 9-cis-RA and 13-cis-
RA in MCF-7 human breast cancer cells, most probably because
of the absence of their oxidative catabolism in these cells.
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Together, these findings extend and confirm the hypothesis that
liarozole-fumarate acts as a versatile inhibitor in the ATRA cata-
bolic pathway (Figure 4), and may show potential in circumven-
tion ofRA resistance in cancer.
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